PRIMARY STUDY
Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment
Key Findings: This systematic review found limited evidence for cannabidiol's antipsychotic efficacy in treating primary psychotic disorders, with no clear benefits for cognition or functioning, but noted a favorable side effect profile compared to other antipsychotics.
Type of Study: Meta-analysis
Study Result: Inconclusive
Research Location(s): Canada
Year of Pub: 2020
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Not Applicable
Citation: Ghabrash MF, et al. Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment. Psychiatry Res. 2020; 286:112890. doi: 10.1016/j.psychres.2020.112890
Authors: Ghabrash MF, Coronado-Montoya S, Aoun J, Gagné AA, Mansour F, Ouellet-Plamondon C, Trépanier A, Jutras-Aswad D
